A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Antiviral Activity, Safety and Tolerability, and Pharmacokinetics of JNJ-64281802 in Participants With Confirmed Dengue Fever
Latest Information Update: 04 Mar 2024
At a glance
- Drugs Mosnodenvir (Primary)
- Indications Dengue
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 11 Oct 2023 Status changed from suspended to discontinued.
- 12 May 2023 Status changed from recruiting to suspended.
- 25 Oct 2022 Planned primary completion date changed from 19 Aug 2022 to 15 Nov 2024.